Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Aortech International Plc LSE:AOR London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 126.50 123.00 130.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.5 -0.6 -4.7 - 20

Aortech Share Discussion Threads

Showing 8826 to 8845 of 8900 messages
Chat Pages: 356  355  354  353  352  351  350  349  348  347  346  345  Older
DateSubjectAuthorDiscuss
10/6/2020
12:56
Nice to see you back Stig, interesting article, on the Clinical trial info on Foldax: Principal Investigator: Amit Patel, MD Utah Looks like Frank picks his friends well.
landy90
10/6/2020
12:53
Looking to breakout of the channel and take-on technical areas that have been in place for years.
greedy rooster
10/6/2020
12:30
Wow Foldax not coming out of this Surgisphere scandal looking very good htTps://www.sciencemag.org/news/2020/06/whos-blame-these-three-scientists-are-heart-surgisphere-covid-19-scandal
the stigologist
10/6/2020
11:29
bones - you have a DM - thanks. :)
herschel k
10/6/2020
11:28
The bones' note seems to be having an effect
someuwin
10/6/2020
08:54
I've topped up again here this morning, in a broken world, this looks to be such a good opportunity. It looks to me like Mr market wants to hold it around these levels to accumulate positions ahead of the next run up which the pipeline of news flow could underpin. Good luck all.
greedy rooster
09/6/2020
12:23
Thank you bones for forwarding your note onto me. It's a well structure document pooling information from the forum's headers and posts. A great introduction for anyone considering investing with references for further reading/viewing.
cfb2
09/6/2020
12:05
Well looks like there's a number of good sized buys following Bones' note, well done.
nimbo10
09/6/2020
11:08
Someuwin, management is aware of my note as I wanted to clarify certain areas of technical matters relating to the work being done on the valves and generally ensuring I did not misrepresent any facts. Those were my requests to the company to check for accuracy and reasonableness. It is however an independent undertaking on my part and nothing was changed that I didn't assent to. Therefore, I don't expect the company to distribute it as they didn't commission it. They have deals with ED and Shore for that side of things. We are all rowing in the same direction, I hope!
bones
09/6/2020
10:50
Can't disagree, GR. It's all about execution now (including being extraordinarily prudent with cash and generally getting it right on financing) and they've done a sterling job in the executing during these last two years.
bones
09/6/2020
10:18
I haven't seen your note bones, but I'd be interested to know if you've had any feedback from AOR management. And whether they could distribute it?
someuwin
09/6/2020
10:12
Equity Developments value at circa £100m. This should increase as the success chance of the first two products in development increases and the path to value realisation becomes visible. This has the potential to ten bag and more IMO from here over the next two years if all proceeds to plan, regulatory approval and a path to commercialisation crystallises. Not bad against the current market backdrop.
greedy rooster
09/6/2020
09:00
Well done!
langland
09/6/2020
08:51
I am grateful to no less than EIGHT of you that have so far requested a copy of my research PDF (laid out in post 3594). I am equally humbled by the kind responses! One respected, material shareholder of AOR even thought that it is the kind of material Shore Capital should be sending out to their clients! Very kind words. Judging by the replies, it is clear to me, by extrapolation, that there are many serious, long term shareholders of AOR lurking and observing from the shadows and it is encouraging that some have indicated that they will pass the document around their own circle of investor friends and associates. The more the general message can be circulated amongst serious players, the more that will take a look at the story unfolding here at Aortech/RUA.
bones
08/6/2020
17:48
Thanks Landy90. They retain 690p valuation. Today’s share price 110p. Bull market anyone? ED note can be seen here: https://research.equitydevelopment.co.uk/hubfs/Research/RUA%20Medical/AorTech%20International%20plc%20%20%20%20%20%208%20June%202020.pdf
bones
08/6/2020
17:47
Yes , its been another good month of newsflow . Dr Andy Smith at Equity Development reviews the announcements and retains 690p / share fair value . See note here : https://tinyurl.com/yd29j759
edmonda
08/6/2020
17:36
Another research note out from Equity Development summarising the string of recent good news.
landy90
08/6/2020
10:12
I have just written a short research document of 4 pages plus some reference links, on the current state of play at Aortech/RUA following the “merger” between Aortech and RUA Medical Devices Ltd in April and the immense steps forward taken by those combined companies in the development to date in readiness for various trials of the heart valve and cardiovascular grafts. The piece briefly talks about: - The merger’s benefits in terms of vertical integration and combination of manufacturing expertise and valuable IP. - The current industry landscape and how Aortech/RUA could disrupt it. - The heart valve industry, current technologies and why Aortech/RUA have such a large opportunity to hurt the majors if they are successful. - The historical tendency for the majors to defend their positions by buying out disrupters. - The possibility that Aortech/RUA has two current projects that each could ultimately be worth many multiples of the current share price of Aortech/RUA. - The pipeline of other areas of devices that RUA has brought with it that could in future be exploited via the Elast-Eon IP platform. It does NOT discuss finances and future funding needs, which are inevitable at some stage. It does however cross-refer to documents where those subjects do get an airing, eg the Equity Development research notes. I would emphasise that this is, first and foremost, intended as an initial source of information, a “research starter pack” with cross referencing to various other sources of information. It is to be used as such and is not in any way a recommendation to invest. That decision is for someone after they have done their own research way beyond my little effort! It was written primarily for some high net worth individuals who expressed an interest through an associate of mine. If anyone here is interested in seeing the piece or knows any serious investors who might want to know a bit more information about the company for their own researches, please send a PM with name and email address and I’ll send a PDF of it to you. As I state on the document, this is not intended for wide distribution, is not for commercial purposes nor any recommendation to invest. Lest we all forget that this is still a high risk investment with plenty of challenges ahead for the management!
bones
08/6/2020
07:13
08 June 2020 AorTech International plc ("AorTech", the "Company" or the "Group") Update on Elective Surgery and Customer Orders AorTech International plc (AIM: AOR.L), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon (TM) ), provides the following update on customer orders received by its recently acquired wholly-owned subsidiary, RUA Medical Devices Limited ("RUA"). Resumption of Orders On 14 April 2020, AorTech announced that RUA had been notified by its largest customer that, due to US Government (both federal and state) mandates to suspend all elective surgery in hospitals and surgical centres throughout the United States, it was temporarily unable to provide forecasts and orders for the medical devices manufactured for it by RUA. RUA has recently received a further notification from its largest customer requesting it to prepare for the production of products and that orders would resume in the near future, but reserved the right to implement further suspension of orders in the event of the impact of a second wave of COVID-19. Since receipt of this notification, RUA has now received new orders from its largest customer for delivery in August 2020. David Richmond, Group CEO of AorTech, stated : "We are encouraged by this recent communication and the resumption of orders by our largest customer but are mindful that a second wave of COVID-19 could still lead to a further suspension. We are now planning production schedules following the successful completion of a 'Safe working during COVID-19 pandemic' risk assessment. All active staff have been trained to ensure that they are able to work safely and comply with the UK Government's social-distancing guidelines. We look forward to being able to bring those members of staff back from furlough in-line with the production scheduling requirements."
someuwin
04/6/2020
12:26
Market valuations are based on future expectations not just yearly accounting figures. Not much expectation is seen with AOR, this is where well researched holders can capitalize as company developments progress and the market catches up.
nimbo10
Chat Pages: 356  355  354  353  352  351  350  349  348  347  346  345  Older
ADVFN Advertorial
Your Recent History
LSE
AOR
Aortech
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210729 06:07:32